Skip to main content
OpenTrials
Completed

NCT Number: NCT03836144

Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria

It has recently been described the presence of a urinary inflammatory signature in patients with cystinuria, the most common cause of renal lithiasis of genetical origin. These data are very innovative in this pathology but deserve further studies to establish the specificity of this inflammatory signature in patients with cystinuria compared to other nephropathies and other renal lithiasis diseases. Moreover, the effect of the usual treatment of cystinuria (namely urine alkalanization) on urinary inflammatory biomarkers deserves to be tested.

The objectives of the present study are: i) To study the urinary inflammatory profile by mass spectrometry (a very efficient tool to detect and identify proteins) in patients with cystinuria and in patients with lithiasis of other origin and in patients with inflammatory renal disease ; ii) To study the potential effect of urine alkalinazation with potassium citrate (usual treatment according to European recommendations) on the inflammatory signature of patients with cystinuria. To this aim, urine of non treated cystinuric patients will be collected before treatement initiation and 3 months after the start of the alkalizing treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystinuria Congenital, Hereditary, and Neonatal Diseases and Abnormalities Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Glomerulonephritis Inflammation Interstitial Nephritis Kidney Diseases Male Urogenital Diseases Nephritis Nephritis, Interstitial Nephrolithiasis Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Aminoacidurias Renal Lithiasis Renal Tubular Transport, Inborn Errors Urogenital Diseases Urolithiasis Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Eurpean Georges Pompidou Hospital

Paris, Île-de-France Region, 75015, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age superior or equal to 18 years
  • patient able to understand the information note and to sign the informed consent
  • patient with an Health coverage
  • no current urinary tract infection (assessed by a cytobacteriological examination of the urine)
  • For the cystinuria group: patient with cystinuria not yet treated or for whom the alkalizing treatment or the cystein binding thiol agents have been discontinuated for at least 3 months AND with an estimated GFR (using the MDRD formula) greater than 60 ml/min/1.73m2.
  • For the control groups: patient presenting either a renal lithiasis not due to cystinuria, or an inflammatory renal pathology confirmed by an anterior renal biopsy (glomerulonephritis or interstitial nephritis) AND with an estimated GFR (using the MDRD formula) greater than 30 ml/ min/1.73m2.

Exclusion criteria

  • Cystinuric patient already treated (whatever the treatment)

Treatment and study plan

Potassium citrate

Dietary Supplement

Other names: Sodium bicarbonate

Primary outcomes

  1. Change from baseline urine inflammatory profile after 3 months of alkalizing treatment using mass spectrometry in patients with cystinuria.

    Time frame: at inclusion and after three months of the usual alkalizing treatment for the patients with cystinuria

    Study of urine inflammatory biomarkers profile using mass spectrometry to determine if the alkalizing treatment is susceptible to modify the urine inflammatory profile. Proteases inhibitors will be added to the urine sample immediately after urination. Urine will then be frozen at -80°C until mass spectrometry analysis. Mass spectrometry will determine the differential expression of all the proteins present the urine sample. For the purpose of the present study, the investigators will focus on the expression of inflammatory biomarkers among them MMP9 (matrix metallopeptidase), Myeloperoxydase, Proteinase 3, Neutrophil Elastase, Cathepsine G, LSP1 (lymphocyte specific protein), Fibrinogen beta and gamma chains. The aim of mass spectrometry is to detect the presence of proteins in the urine sample and to assess the differential levels of expression of the detected proteins but not to precisely measure the urine concentration of the detected proteins.

Secondary outcomes

  1. Assessment of urine inflammatory profile in controls groups using mass spectrometry.

    Time frame: at inclusion for patients with a nephrolithiasis not due to cystinuria and in patients an inflammatory nephropathy of glomerular or tubulo interstitial origin

    Study of urine inflammatory biomarkers with mass spectrometry in control groups to determine if the urine inflammatory profile is specific to cystinuria. Proteases inhibitors will be added to the urine sample immediately after urination. Urine will then be frozen at -80°C until analysis. Mass spectrometry will determine the differential expression of all the proteins present the urine sample. For the purpose of the present study, the investigators will focus on the expression of inflammatory biomarkers. The aim of mass spectrometry is to detect the presence of proteins in the urine sample and to assess the differential levels of expression of the detected proteins but not to precisely measure the urine concentration of these proteins. Moreover, urine analysis by mass spectrometry will detect all urinary proteins and the investgators do exclude to find unexpected proteins. For those reasons, urine analysis by mass spectrometry is a unique outcome.

  2. Study of crystalluria (presence of crystals in urine) to assess nephrolithiasis activity.

    Time frame: at inclusion for these two groups and after three months of the usual alkalizing treatment for the patients with cystinuria

    Assessment of the presence of crystals in the second morning urine sample in patients with cystinuria and in patients with a nephrolithiasis not due to cystinuria, to assess nephrolithiasis activity.

Other outcomes

  1. Presence of stones in the renal cavities or in the urinary tract using ultrasonograhy.

    Time frame: at inclusion for these two groups and after three months of the usual alkalizing treatment for the patients with cystinuria

    assessment of the presence of urinary stones using ultrasonogrpahy in patients with cystinuria and in patients with a nephrolithiasis not due to cystinuria.

  2. Blood CRP concentrations to assess systemic inflammation

    Time frame: at inclusion for all groups and and after three months of the usual alkalizing treatment for the patients with cystinuria

    Blood CRP concentration (mg/L)

Sponsors and collaborators

Lead sponsor

European Georges Pompidou Hospital

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France
  • Sponsor Name Pending

Registry information

Official study title

Effect of Urine Alkalinazation on Urinary Inflammatory Markers Analyzed Using Mass Spectrometry in Patients With Cystinuria

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Feb 11, 2019
Registry last updated
Mar 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.